Licinio Julio, Wong Ma-Li
Pharmacogenomics Research Group, Department of Translational Medicine, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Dialogues Clin Neurosci. 2011;13(1):63-71. doi: 10.31887/DCNS.2011.13.1/jlicinio.
There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.
药物基因组学有望优化重度抑郁症的现有治疗方法，并确定药物研发的新靶点，人们对此寄予了厚望。人类基因组测序完成后不久，人们曾满怀希望地认为，药物基因组学将迅速取得巨大进展。在过去十年中，这种最初的热情已被更为审慎的乐观态度所取代，因为我们在基于基因组学指导治疗的目标上已经取得了长足进展。虽然将研究成果转化为临床应用的工作仍在进行，但我们现在已经拥有了大量知识以及明确的前进方向。本文将从药效学和药代动力学方面对抑郁症药物基因组学的现状进行批判性评估。
